FGF12 is a novel component of the nucleolar NOLC1/TCOF1 ribosome biogenesis complex

Martyna Sochacka1, Radoslaw Karelus1, Lukasz Opalinski1, Daniel Krowarsch2, Martyna Biadun1, Jacek Otlewski1 and Malgorzata Zakrzewska1*

Abstract

Among the FGF proteins, the least characterized superfamily is the group of fibroblast growth factor homologous factors (FHFs). To date, the main role of FHFs has been primarily seen in the modulation of voltage-gated ion channels, but a full picture of the function of FHFs inside the cell is far from complete. In the present study, we focused on identifying novel FGF12 binding partners to indicate its intracellular functions. Among the identified proteins, a significant number were nuclear proteins, especially RNA-binding proteins involved in translational processes, such as ribosomal processing and modification. We have demonstrated that FGF12 is localized to the nucleolus, where it interacts with NOLC1 and TCOF1, proteins involved in the assembly of functional ribosomes. Interactions with both NOLC1 and TCOF1 are unique to FGF12, as other FHF proteins only bind to TCOF1. The formation of nucleolar FGF12 complexes with NOLC1 and TCOF1 is phosphorylation-dependent and requires the C-terminal region of FGF12. Surprisingly, NOLC1 and TCOF1 are unable to interact with each other in the absence of FGF12. Taken together, our data link FHF proteins to nucleoli for the first time and suggest a novel and unexpected role for FGF12 in ribosome biogenesis.

Keywords: FGF12, Protein-protein interaction, Nucleolus, Ribosome biogenesis, NOLC1, TCOF1

Background

The fibroblast growth factor (FGF) family includes 22 genes found in humans that share sequence and structural similarity [1, 2]. FGFs bind to their specific fibroblast growth factor receptors (FGFRs) and stimulate intracellular signaling pathways [3]. FGFs-induced cellular responses are critical for developmental processes and their deregulation is associated with cancer and metabolic diseases [4]. FGFs fall into three major groups: canonical FGFs (comprising subfamilies 1, 4, 7, 8 and 9), endocrine FGFs, referred to as the FGF19 subfamily, and fibroblast growth factor homologous factors (FHFs), until recently considered intracellular FGFs, termed the FGF11 subfamily [2, 5].

The FHF subfamily consists of four proteins: FGF11, FGF12, FGF13 and FGF14. They contain a 120–130 amino acid conserved domain that folds into a β-trefoil structure, homologous to other FGFs [6]. FHFs lack an N-terminal signal sequence [7, 8] and their secretion, even in an unconventional manner, has not yet been documented. Moreover, FHF proteins are unable to stimulate proliferation in FGFR-positive cells [9]. They were therefore considered to be exclusively intracellular proteins whose function is independent of cell surface FGFRs. This view has recently been partially challenged by us and others, who have shown that recombinant FHFs are capable of directly binding and activating FGFR and inducing receptor-downstream signaling pathways [9, 10], leading to an anti-apoptotic cellular response [9]. Each intracellular FHF is represented by at least two distinct isoforms, differing at the N-terminus and resulting from alternative splicing [8]. The isoform determines the cellular localization of FHFs, with the “a” isoform containing...
an N-terminal bipartite nuclear localization signal (NLS) directing the protein to the nucleus, while the shorter “b” isoform, lacking the NLS, is predominantly localized in the cytosol [11].

The main function of FHF proteins, so far, has been attributed to their cytosolic localization, where they act as intracellular modulators of plasma membrane voltage-gated ion channels [11–16]. In addition, cytosolic FHFs form signal transducing complexes with partner proteins such as islet-brain-2 (IB2), NF-kB essential modulator (NEMO), hypoxia-inducible factor-1α (HIF-1α), casein kinase 2 (CK2), glycogen synthase kinase 3 (GSK3) and (JAK2) [1, 17–25]. Although FHFs have been observed in the cell nucleus [26], their biological role there remains a mystery.

Based on the first comprehensive mass spectrometry (MS)-based analysis of the FGF12 interactome, we present here the newly identified FGF12 interactors. We found a group of nucleolar proteins, including NOLC1 (nucleolar and coiled-body phosphoprotein 1; Nopp140) and TCOF1 (treacle ribosome biogenesis factor 1; Treacle), that provide insights into a new and unexpected role for FGF12 in the nucleus.

Methods
Antibodies and reagents
The anti-FGF12 antibody (#PA5-67182) was from Thermo Fisher Scientific (Waltham, MA, USA). The primary antibodies: anti-NOLC1 (#sc-374033), anti-TCOF1 (#sc-374536), anti-THRAP3 (#sc-133250), anti-BCLAF1 (#sc-101388), anti-dyskerin (#sc-373956), anti-FGF12 (#sc-81947), anti-SBP (#sc-101595), anti-histone H3 (#sc-10809), anti-His-tag (#sc-8036) were from Santa Cruz (Dallas, TX, USA). The primary antibodies: anti-phospho-FGFR (Tyr653/Tyr654) (#06-1433), anti-phospho-p44/42 MAP kinase (p-ERK1/2) (#9101), anti-p44/42 MAP kinase (ERK1/2) (#9102) were from Cell Signaling (Danvers, MA, USA). The primary antibodies: anti-NOLC1 (#HPA037366) and anti-γ-tubulin (tubulin) (#T6557) were from Sigma-Aldrich (St Louis, MO, USA). The anti-GFP antibody (#50430-2-AP) was from Protein-Tech (Chicago, IL, USA). Horseradish peroxidase-conjugated secondary antibodies and the anti-mouse secondary antibody conjugated to Alexa Fluor 594 (#715-585-150) were from Jackson ImmunoResearch (Cambridge, UK). The secondary anti-rabbit antibody conjugated to Alexa Fluor 594 (#A11037) was from Thermo Fisher Scientific.

Pierce Anti c-myc Magnetic Beads (#88843) and Streptavidin agarose resin (#20353) were from Thermo Fisher Scientific. Ni Sepharose 6 Fast Flow resin (#GE17-5318-02) was from GE Healthcare (Chicago, IL, USA).

siRNA against NOLC1 (#sc-38127) and TCOF1 (#sc-61707) were from Santa Cruz. The non-targeting control siRNA (#D-001810-01-50) and siRNA against FGF12 [27] was ordered from Horizon Discovery (Waterbeach, UK). Calf intestinal alkaline phosphatase (CIP) was from Sigma-Aldrich (#P4978-1KU). Nuclease was from Thermo Fisher Scientific (#88701).

Cells
The human osteosarcoma (U2OS) cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Biowest, Nauille, France) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin) (Thermo Fisher Scientific). Stable U2OS-FGF11-GFP-myc, U2OS-FGF12-GFP-myc, U2OS-FGF13-GFP-myc, U2OS-FGF14-GFP-myc and U2OS-FGF12-SBP cell lines were obtained from U2OS cells transfected with pcDNA3.1 vectors containing sequences encoding the ‘a’ isoforms of individual FHFs in fusion with GFP-myc or SBP (Gene Universal, Newark, DE, USA) using FuGene HD transfection reagent (Roche, Indianapolis, IN, USA). Cells were replated 24 h after transfection and cultured in selection medium (growth medium with 1 mg/ml geneticin (G-418) (BioShop, Canada) until colony formation was observed. Colonies were transferred using cloning discs (Sigma-Aldrich) to 6-well plates and then to T-75 cm² flask for continued culture under the same conditions. Expression of FGFs was confirmed by western blotting using antibodies specific for GFP and FGFs. Human embryonic kidney cells (HEK 293) obtained from ATCC were cultured in DMEM supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin). Mouse embryo fibroblast cells (NIH3T3) were obtained from ATCC and were cultured in DMEM supplemented with 10% bovine serum (BS) and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin). All cell lines were grown in a 5% CO₂ atmosphere at 37 °C. Cells were seeded onto tissue culture plates one day before the experiments.

Recombinant proteins
Phusion Inverse PCR mutagenesis was applied to obtain the 131–181 FGF12 deletion mutant (FGF12Δ-His), using pDEST17-FGF12 as a template. The primers contained a STOP codon at the protein truncation site. Expression and purification of recombinant his-tagged FGF12 variants were performed as previously described [9].
siRNA transfection
siRNA transfections were performed with DharmaFECT Transfection Reagents (Horizon, Cambridge, UK) according to the manufacturer’s instructions. Cells were transfected with 100 nM siRNA against NOLC1, TCOF1 or FGF12, and after 24 h the transfection medium was replaced with complete medium. Control cells were transfected with 100 nM non-targeting siRNA. Cells were incubated in a 5% CO2 atmosphere at 37 °C for another 48 h.

Fluorescence microscopy
To investigate the localization of FGFs proteins stably expressed in fusion with GFP, U2OS-FGF11-mGFP-myc, U2OS-FGF12-mGFP-myc, U2OS-FGF13-mGFP-myc, U2OS-FGF14-mGFP-myc cells were fixed with 4% paraformaldehyde. Nuclei were stained with NucBlue Live (Thermo Fisher Scientific). For quantification, the mean fluorescence intensity of each compartment was measured using Zeiss ZEN 2.3 software. To calculate the amount of fluorescent FHFs in each compartment, the mean intensity of fluorescence was multiplied by the area of the respective compartment.

To analyze the co-localization of FGF12-mGFP-myc and their protein partners, U2OS-FGF12-mGFP-myc cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton in PBS. Cells were then stained with mouse anti-NOLC1, anti-TCOF1, anti-dyskerin, anti-THRAP3, anti-BCLAF1 primary antibodies and Alexa Fluor 594-conjugated anti-mouse secondary antibody. Cell nuclei were stained with NucBlue Live dye. Wide-field fluorescence microscopy was carried out using a Zeiss Axio Observer Z1 fluorescence microscope (Zeiss, Oberkochen, Germany). Images were captured using an LD-Plan-Neofluar 40 × /0.6 Korr M27 objective and an Axiocam 503 camera. The red PLA signal was visualized using a 540/552 nm bandpass excitation filter and a 575/640 nm bandpass emission filter, and the FGF12-mGFP-myc signal was visualized with a 450/490 nm bandpass excitation filter and a 500/550 nm bandpass emission filter. The NucBlue Live signal was visualized using a 335/383 nm bandpass excitation filter and a 420/470 nm bandpass emission filter. Images were processed with Zeiss ZEN 2.3 software.

Proximity ligation assay (PLA)
To analyze the interaction of FGF12, NOLC1 and TCOF1, U2OS-FGF12-GFP-myc cells or HEK 293 cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton in PBS. Cells were then stained with antibodies against NOLC1 and FGF12, TCOF1 and FGF12 or NOLC1 and TCOF1 in combination with secondary PLA probes according to the manufacturer’s protocols (Duolink In Situ PLA, Sigma-Aldrich).

Pull-down
To confirm the interaction of FGF12 with proteins identified in MS experiments, recombinant FGF12 was bound to Ni Sepharose Resin (1 h, 4 °C) and incubated with U2OS cell lysed in lysis buffer (0.15 M KCl, 40 mM Tris, 1% NP-40, 1 mM EDTA, 0.1 mM PMSF, pH 7.2), supplemented with protease and phosphatase inhibitor cocktails (Roche), overnight at 4 °C. The resin was washed three times with PBS and bound proteins were eluted with Laemmli sample buffer. Proteins were separated by SDS-PAGE and analyzed by Western blotting using the following antibodies: anti-NOLC1, anti-TCOF1, anti-BCLAF1, anti-THRAP3 and anti-FGF12.

To study the interaction between FHFs and NOLC1 or TCOF1, U2OS-FGF12-GFP-myc (or U2OS-FGF12-SBP), U2OS-FGF11-mGFP-myc, U2OS-FGF12-mGFP-myc, U2OS-FGF13-mGFP-myc, U2OS-FGF14-mGFP-myc cells were lysed in lysis buffer (0.15 M KCl, 40 mM Tris, 1% NP-40, 1 mM EDTA, 0.1 mM PMSF, pH 7.2) supplemented with protease and phosphatase inhibitor cocktails and incubated with Pierce Anti c-myc Magnetic Beads or Streptavidin agarose. The resin was washed two times with PBS and the bound proteins were eluted with Laemmli sample buffer. Proteins were separated by SDS-PAGE and analyzed by Western blotting using antibodies recognizing: GFP, NOLC1 or TCOF1. U2OS cells were used as a control.

2D Blue native/SDS-PAGE
U2OS-FGF12-SBP cell was lysed in lysis buffer (0.15 M KCl, 40 mM Tris, 1% NP-40, 1 mM EDTA, 0.1 mM PMSF, pH 7.2) supplemented with protease and phosphatase inhibitor cocktails and incubated with Streptavidin agarose resin overnight in 4 °C. The resin was then washed three times with PBS, and bound proteins were eluted with 4 mM biotin in lysis buffer and separated by BN-PAGE on 4–13% gradient gels. For two-dimensional analysis, individual complexes were analyzed in the 1st dimension by BN-PAGE, and then isolated and separated by SDS-PAGE in the 2nd dimension. After electrophoresis, proteins were transferred to a PVDF membrane and detected with anti-NOLC1, anti-TCOF1 and anti-FGF12 antibodies.

Cell fractionation
To fractionate cells into cytoplasmic and nuclear fractions, U2OS cells stably expressing FGF11-mGFP-myc, FGF12-mGFP-myc, FGF13-mGFP-myc, FGF14-mGFP-myc were lysed in lysis buffer (0.15 M KCl, 40 mM Tris,
0.1% NP-40, 1 mM EDTA, 0.1 mM PMSF, pH 7.2) supplemented with protease and phosphatase inhibitor cocktails (Roche). The soluble fraction was designated as the cytoplasmic fraction. The insoluble fraction, obtained by centrifugation of the lysates followed by sonication, was designated as the nuclear fraction. FGFs present in different fractions were concentrated by binding to Pierce Anti-c-myc Magnetic Beads. The presence of FGF11, FGF12, FGF13, FGF14 or marker proteins (ERK1/2 and histone-H3), confirming the purity of the fractions, was analyzed by immunoblotting.

To isolate nucleoli, U2OS-FGF12a-GFP-myc cells were lysed in lysis buffer for 20 min on ice. After centrifugation, the pellet was resuspended in 0.5 M sucrose and sonicated, layered over a cushion of 1 M sucrose and centrifuged to pellet nucleoli. The nucleoli were washed by resuspension in 0.5 M sucrose followed by centrifugation. The nucleoli were resuspended in the same volume of Læmmli sample buffer used to prepare sample from total lysate. The presence of FGF12 and NOLC1 was analyzed by immunoblotting.

**FGFR1 activation and downstream signaling**

Serum-starved NIH3T3 cells were treated with FGF12Δ-His or FGF1 (as control) in the presence of heparin (10 U/ml) (Sigma-Aldrich) for 45 min. Cells were lysed with Laemmli sample buffer and lysates were subjected to SDS-PAGE and western blotting.

**Mass spectrometry analysis**

To identify binding partners of FGF12, we used recombinant His-tagged FGF12, which was coupled to NiNTA resin and incubated with U2OS cell lysate. Mass spectrometry analysis was performed by the Mass Spectrometry Laboratory at the Institute of Biochemistry and Biophysics, Polish Academy of Sciences (Warsaw, Poland). Beads with proteins were subjected to a standard trypsin digestion procedure, where proteins were reduced with 5 mM TCEP for 1 h at 60 °C, blocked with 10 mM MMTS for 10 min at RT and digested overnight with trypsin (0.1 mg/ml). After digestion, the peptides were dried in a SpeedVac and purified using a modified SP3 procedure [28]. Briefly, tryptic peptides were resuspended in 20 µl of water with 0.1% formic acid (FA) and bound in the presence of acetonitrile (ACN) to 15 µl of bead mix prepared by combining equal parts of SeraMag Carboxyl hydrophilic and hydrophobic particles (09-981-121 and 09-981-123, GE Healthcare). Peptides were washed twice with 1 ml of ACN and eluted with 200 mM ammonium hydroxide. The dried peptides were then resuspended in 50 µl of 2% ACN and 0.1% FA. The peptide mixtures were applied in equal volumes of 20 µl to an RP-18 pre-column (Waters, Milford, MA, USA) using water containing 0.1% FA as a mobile phase and then transferred to an RP-18 nano-HPLC column (internal diameter 75 µm, Waters) using an ACN gradient (0–35% ACN in 160 min) in the presence of 0.1% FA at a flow rate of 250 nI/min. The column outlet was coupled directly to the ion source of the Q Exactive mass spectrometer (Thermo Fisher Scientific) operating in DDA mode with Top2 ions subjected to the fragmentation after each full scan with a scan range from 300 to 1650 m/z. Each analysis was preceded by a blank run to ensure no cross-contamination from previous samples.

Acquired MS/MS data from triplicates were preprocessed with Mascot Distiller software (v. 2.6, MatrixScience) and searched using Mascot Search Engine (MatrixScience, Mascot Server 2.6) against the human proteins deposited in Swissprot 2019_11 database (20,442 sequences). To reduce mass errors, peptide and fragment mass tolerance settings were determined separately for each LC-MS/MS runs after recalibration of the measured mass, as described previously [29]. Statistical assessment of peptide assignment confidence was based on a target/decoy database search strategy [25]. This procedure provided q-value estimates for each peptide spectrum match in the data set. All queries with q-values >0.01 were removed from further analysis. The mass calibration and data filtering described above were performed using MScan software developed in-house (http://proteom.ibb.waw.pl/mscan/).

**Results**

**FGF12 is a novel component of nucleolar protein complexes**

FGF12 is a pleiotropic protein involved in modulation of voltage-gated ion channel, cellular signaling, reactive oxygen species (ROS) and apoptosis [9, 30–35]. The versatility of FGF12 activities implicates that this protein may be part of various protein complexes inside the cell. However, unbiased screening to decipher the map of FGF12 intracellular interactions has not yet been performed. We used functional recombinant His-tagged FGF12 [9], which was coupled to Ni Sepharose resin and incubated with U2OS cell lysate (Fig. 1A). Proteins specifically bound to FGF12-His were identified by MS, yielding more than 70 proteins (Additional file 1: Table S1). Among the top hits, several ribosomal proteins and two major components of the nucleolar ribosome biogenesis complex were found: nucleolar and coiled-body phosphoprotein 1 (NOLC1; Nopp140; Uniprot ID: Q14978) and treacle ribosome biogenesis factor 1 (TCOF1; Treacle; Uniprot ID: Q13428) (Fig. 1B, C). Interestingly, functional classification of all identified FGF12 interactors indicated multiple ribosomal components closely related
to NOLC1/TCOF1 via RSL1D1, RPS14 and RPL18A (Fig. 1C).

In the next step, we verified the localization of FGF12 in U2OS cells. To this end, we stably transfected U2OS cells with the FGF12-mGFP-myc expression construct (Additional file 2: Fig. S1) and monitored the subcellular localization of FGF12-mGFP-myc with fluorescence microscopy. We observed a weak mGFP signal in the cytoplasm, while most of the fluorescence was detected in the nuclei of U2OS cells (Fig. 1D). Surprisingly, inside the nuclei, the FGF12-mGFP-myc signal accumulated in characteristic, well-defined structures specific to the nucleoli (Fig. 1D), compartments rich in the NOLC1/TCOF1 complex and several other proteins identified by us in MS experiments (Additional file 1: Table S1). The nucleolar localization of FGF12 was validated by fluorescence microscopy using an antibody against a specific nucleolar protein, dyskerin (Fig. 1E) [36–38]. Next, we isolated nucleoli from U2OS cells stably transfected with FGF12-mGFP-myc and confirmed the presence of FGF12 in the NOLC1-positive nucleoli-enriched fraction (Fig. 1F).

To analyze whether the nucleolar localization of FGF12 is unique to FGF12 or whether it is a common feature shared by the family of fibroblast growth factor homologous factors (FHF), we stably transfected U2OS cells with expression vectors providing FGF11-mGFP-myc, FGF13-mGFP-myc and FGF14-mGFP-myc production (Additional file 2: Fig. S1A) and proceeded with fluorescence microscopy. As shown in Additional file 2: Fig. S1B and S1C, all FHF members were found in the nucleoli of U2OS cells, albeit in different amounts. While the FGF12-mGFP-myc and FGF13-mGFP-myc signal predominated in nucleoli, with accumulation in nucleoli, the FGF11-mGFP-myc was detected in both nuclei and cytoplasm, with only trace fluorescence in nucleoli (Additional file 2: Fig. S1B, C). For the FGF14-mGFP-myc protein, a signal was still visible in the nucleoli, but it was weaker than that observed for FGF12-mGFP-myc and FGF13-mGFP-myc. For all FHF, we confirmed cytoplasmic and nuclear localization using cell fractionation and western blotting (Additional file 2: Fig. S1D). We verified MS interaction data using Ni Sepharose pull-down with recombinant FGF12-His and cell lysate prepared from U2OS cells. Western blotting with antibodies specific for the top MS-listed nucleolar proteins: NOLC1, TCOF1, BCLAF1 and THRAP3 revealed their efficient co-purification with FGF12-His (Fig. 2A). Using immunolabeling and fluorescence microscopy, we confirmed co-localization of FGF12-mGFP-myc with NOLC1, TCOF1, BCLAF1 in cell nucleoli and THRAP3 in the nucleus of U2OS cells (Fig. 2B). These data indicate that FGF12 is a novel nucleolar protein involved in a multifaceted interaction network centered on the NOLC1/TCOF1 complex involved in the binding of multiple ribosomal proteins (Fig. 1C).

**FGF12 interacts with NOLC1/TCOF1 in a phosphorylation-dependent manner**

Because the NOLC1/TCOF1 complex was at the top of the MS hit list for FGF12 binding partners and because of the critical role of NOLC1/TCOF1 in ribosome biogenesis, we decided to focus on the FGF12-NOLC1/TCOF1 interaction. To confirm that FGF12 and NOLC1/TCOF1 form complex(es) inside cells, we applied pull-down experiments with anti-myc agarose using U2OS and U2OS cells stably transfected with FGF12-mGFP-myc. As shown by SDS-PAGE followed by western blotting analysis in Fig. 3A, both NOLC1 and TCOF1 were efficiently co-purified with FGF12-mGFP-myc. We confirmed these data by streptavidin-agarose pull-down using U2OS cells stably transfected with FGF12-SBP (Additional file 3: Fig. S2A, B). In addition, we used streptavidin-agarose pull-down from U2OS stably expressing FGF12-SBP cells (U2OS–FGF12-SBP) to purify FGF12-SBP complexes under native conditions (eluted with biotin) and analyzed...
Fig. 1  (See legend on previous page.)
Fig. 2 Interaction of FGF12 with nucleolar proteins. 

A Verification of the results of MS experiments. Recombinant FGF12-His was bound to Ni Sepharose and incubated with U2OS cells lysate. FGF12-bound proteins were eluted and analyzed by western blotting using specific antibodies. 

B Co-localization of FGF12-mGFP-myc with identified partner protein. To analyze the co-localization of FGF12-mGFP-myc with NOLC1, TCOF1, BCLAF1, THRAP3, U2OS-FGF12-mGFP-myc cells were fixed, permeabilized and stained with appropriate primary antibodies and Alexa Fluor 594-conjugated anti-mouse secondary antibody. Cell nuclei were labeled with NucBlue Live and cells were analyzed by fluorescence microscopy. The scale bar represents 20 μm.
the presence of NOLC1 and TCOF1 in FGF12 complexes using 2D-PAGE. As shown in Additional file 3; Fig. S2C, the FGF12-SBP signals overlapped significantly with those of NOLC1 and TCOF1, indicating efficient purification of high molecular weight FGF12/NOLC1/TCOF1 complexes.

Furthermore, we employed a proximity ligation assay (PLA) to study the subcellular localization of FGF12 complexes with NOLC1 and TCOF1. In U2OS cells stably expressing FGF12-mGFP-myc, PLA signals for both FGF12-NOLC1 and FGF12-TCOF1 pairs largely overlapped with mGFP fluorescence, indicating that FGF12/NOLC1/TCOF1 complexes are mainly localized to nucleoli (Fig. 3B, Additional file 4: Fig. S3). Using a similar experimental setup, we also confirmed the interaction between FGF12, NOLC1 and TCOF1 in HEK293 cells lacking ectopic FGF12 (Additional file 5; Fig. S4).

NOLC1 and TCOF1 are heavily phosphorylated nucleolar proteins. To investigate whether the interaction of FGF12 with NOLC1 and TCOF1 depends on their phosphorylation status, we used a Ni Sepharose pull-down assay with recombinant FGF12-His and calf intestinal alkaline phosphatase (CIP)-treated U2OS cell lysates. CIP efficiently de-phosphorylated both NOLC1 and TCOF1, which is evident as an acceleration of their migration in the gel (Fig. 3C, lanes 1, 2). De-phosphorylation completely inhibited the interaction of NOLC1 with FGF12 and significantly blocked the binding of TCOF1 to FGF12 (Fig. 3C, lane 5). In contrast, the interaction of FGF12 with NOLC1 and TCOF1 is nucleic acid-independent, as nuclease treatment had no effect on the co-purification efficiency of FGF12 with NOLC1 and TCOF1 (Fig. 3D, lane 5).

To investigate which region of FGF12 is involved in NOLC1 and TCOF1 recognition, we prepared a recombinant FGF12Δ-His variant containing most of the FGF core domain but lacking 47 C-terminal residues, including the 12th β-strand (Fig. 3E). FGF12Δ-His retained the ability to bind and activate FGFR1 (Fig. 3F, lane 2), but was virtually incapable of binding NOLC1 and TCOF1 (Fig. 3G, lane 3).

Since we have identified, not only FGF12, but all other FGFs: FGF11, FGF13 and FGF14 in nucleoli, we decided to test whether these proteins are capable of binding NOLC1/TCOF1. To this end, U2OS cells stably transfected with FGF11-mGFP-myc, FGF12-mGFP-myc, FGF13-mGFP-myc, FGF14-mGFP-myc were subjected to anti-myc agarose pull-down, and the co-purification efficiency of NOLC1 and TCOF1 was assessed by western blotting. While NOLC1 was co-purified with all FGF members, TCOF1 was only detected in the elution fraction of FGF12-mGFP-myc cells (Fig. 3H).

All these data strongly indicate that the nucleolar pool of FGF12 is part of the NOLC1/TCOF1 complex. The association of FGF12 with NOLC1/TCOF1 is strictly dependent on NOLC1 and TCOF1 phosphorylation and requires the C-terminal region of FGF12.

**Complexes of NOLC1 and TCOF1 required FGF12 for their nucleolar localization**

To study the importance of NOLC1 and TCOF1 for the nucleolar localization of FGF12, we knocked-down NOLC1 or TCOF1 with siRNA in U2OS-FGF12-mGFP-myc cells (Fig. 4A, Additional file 6: Fig. S5). Silencing of either NOLC1 or TCOF1 had no effect on the nucleolar localization of FGF12-mGFP-myc (Fig. 4A). Furthermore, FGF12 knock-down also did not affect the localization of NOCL1 and TCOF1.

However, PLA experiments revealed that silencing of only one binding partner, NOLC1 or TCOF1, resulted...
Fig. 3 (See legend on previous page.)
Fig. 4 Role of FGF12 in the nucleolar localization of NOLC1 and TCOF1 and the assembly of their complexes. A Fluorescence microscopy analysis of the nucleolar localization of FGF12, NOLC1 and TCOF1 upon silencing of individual proteins. U2OS-FGF12-mGFP-myc cells, transfected with siRNA targeting NOLC1, TCOF1, FGF12 or scramble siRNA (control), were fixed, permeabilized and stained with anti-NOLC1 or anti-TCOF1 primary antibodies and Alexa Fluor 594-conjugated secondary antibody. Cell nuclei were labeled with NucBlue Live and cells were analyzed by fluorescence microscopy. The scale bar represents 20 μm. B Fluorescence images of in situ PLA using anti-FGF12, anti-NOLC1 and anti-TCOF1 antibodies in U2OS-FGF12-mGFP-myc cells upon NOLC1, TCOF1 (n = 3) or FGF2 (n = 2) silencing. Cell nuclei were labeled with NucBlue Live and cells were analyzed by fluorescence microscopy. The dashed line indicates the cell area. The scale bar represents 20 μm. Data shown in the graphs are PLA signal intensity in nuclei. Student’s t-test was applied for statistical analysis; ***p < 0.001
in a partial re-localization of FGF12/TCOF1 and FGF12/NOLC1 complexes from the nucleolus to the nucleus (Fig. 4B). In addition, PLA signals for FGF12/TCOF1 and FGF12/NOLC1 pairs were significantly enhanced upon NOLC1 and TCOF1 knocking-down (Fig. 4B). A similar effect was observed in HEK293 cells (Additional file 7: Fig. S6). These data indicate that the presence of NOLC1 or TCOF1 is not required for nucleolar localization of FGF12. However, silencing of one of the FGF12 binding proteins (NOLC1 or TCOF1) resulted in increased level of FGF12 in complex with the other partner.

Surprisingly, FGF12 silencing resulted in complete inhibition of the interaction between NOLC1 and TCOF1, demonstrating that FGF12 is an integral component of NOLC1/TCOF1 complexes (Fig. 4B).

Discussion

FHFs are pleiotropic proteins whose dysregulation is associated with disorders of the nervous system, cardiac diseases and cancer [19, 39–53]. The specificity of FHFs function appears to be largely determined by their subcellular localization. FHF members lack a signal sequence for secretion and have therefore been recognized as intracellular proteins, acting mainly as regulators of the plasma membrane-embedded voltage-gated ion channels [30, 54–58]. FHFs have been identified in the cytosol and in the nucleus. Although evidence for FHFs secretion is still lacking, several studies indicate that exogenous FHFs bind and activate FGFRs, triggering a protective response of the cell by preventing apoptosis [9, 33–35].

In this study, we have revealed a novel and very intriguing localization of FHF proteins. We found that all FHF family members reside in the nucleolus, however we observed that subcellular distribution (into nucleolus, nucleus and cytosol) differs between distinct FHF members. Furthermore, using FGF12 as an exemplary FHF, we performed the first MS-based identification of FHF cellular interaction network. Among the identified binding partners of FGF12 we found several nucleolar proteins, including NOLC1 and TCOF1. NOLC1 is a cellular target of the anti-cancer drug doxorubicin and natively unfolded scaffold protein that shuttles between the nucleolus and the cytosol, affecting the cellular localization of its binding partners [59–61]. In the nucleolus, NOLC1 forms a complex with its parologue TCOF1 [62], a protein mutated in ribosomopathies as Treacher-Collins Syndrome (TCS). Assembly of the NOLC1/TCOF1 complex occurs in a ubiquitination-dependent manner, and this complex links RNA polymerase I to ribosome-modifying enzymes, to regulate the translation process of cells differentiating towards neural crest specification [62–64]. NOLC1 and TCOF1 are also involved in maintaining genomic stability by acting as DNA damage response (DDR) factors [65].

Here, we have provided robust evidence for the unexpected involvement of FGF12 in nucleolar NOLC1/TCOF1 complexes. Our data indicate that nucleolar localization of FGF12 is independent of the presence of NOLC1 or TCOF1. However, both proteins are required to form FGF12 nucleolar complexes, as knock-down of NOLC1 or TCOF1 partially relocates FGF12/TCOF1 and FGF12/NOLC1 complexes to the nucleus. Silencing one of the FGF12 binders (NOLC1 or TCOF1) increases the level of the FGF12 complex with the other partner. Moreover, FGF12 appears to be central to the NOLC1/TCOF1 interaction. The binding of FGF12 to NOLC1 and TCOF1 is phosphorylation-dependent. Since NOLC1, TCOF1 and FHF are CK2 substrates or CK2 binding partners [65, 66], CK2 may constitute a major regulator for nucleolar assembly of the FGF12/NOLC1/TCOF1 complex.

At this stage, the role of nucleolar FGF12/NOLC1/TCOF1 complex is still unclear, but it is tempting to speculate that FGF12 may be an important player either in ribosome biogenesis or the DDR. While nucleolar localization and interaction with NOLC1 are conserved for all members of the FHF family, only FGF12 binds both NOLC1 and TCOF1. These findings suggest that distinct FHF proteins may contribute differently to NOLC1/TCOF1 activities. As FHFs and NOLC1/TCOF1 are implicated in severe disease, including epilepsy, cancer and ribosomopathies, future studies should aim to decipher the functional interplay between FHF proteins and NOLC1/TCOF1.

Abbreviations

BCLAF1: Bcl-2-associated transcription factor 1; CB2: Cooxamissil brilliant blue; CIP: Calf intestinal alkaline phosphatase; CK2: Casein kinase 2; DDR: DNA damage response; ERK1/2: Extracellular signal-regulated kinases 1 and 2; FGFR: Fibroblast growth factor receptor; FGF: Fibroblast growth factor; FH: Fibroblast homologous factor; GFP: Green fluorescent protein; MS: Mass spectrometry; NOLC1: Nucleolar and coiled-body phosphoprotein 1; PLA: Proximity ligation assay; RSL1D1: Ribosomal L1 domain-containing protein 1; RPS14: Ribosomal protein S14; RPL18A: Ribosomal protein L18; SBP: Streptavidin binding peptide; TCOF1: Treacle ribosome biogenesis factor 1; TCS: Treacher Collins syndrome; THRAp3: Thyroid hormone receptor-associated protein 3.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12964-022-01000-4.

Additional file 1: Table S1. Results of MS-based peptide identification for proteins that bind specifically to FGF12-His in pull down experiments. ID is the Uniprot protein identifier. The score and peptide match for each of two repeats of the experiment are given.

Additional file 2: Fig. S1. Figure S1. Cellular localization of FHF proteins. A Western blotting analysis of whole cell lysates detecting mGFP in U2OS cells stably transfected with FGF11-mGFP-myc, FGF12-mGFP-myc, FGF13-mGFP-myc, FGF14-mGFP-myc or U2OS cells (control) to confirm the expression of fusion proteins. B Localization of FHF proteins in U2OS cells stably transfected with FGF11-mGFP-myc, FGF12-mGFP-myc, FGF13-mGFP-myc and FGF14-mGFP-myc. Nuclei were labeled with NucBlue Live.
and cells were analyzed with fluorescence microscopy. The dashed line indicates the cell area. The scale bar represents 20 μm. 

**Additional file 3: Fig. S2.** Streptavidin agarose pull-down from U2OS cells stably expressing FGF12-SPB. A Western blotting of cell lysates of U2OS-FGF12-SPB and U2OS cells (control) to confirm FGF12-SPB expression. B U2OS-FGF12-SPB and U2OS cells were lysed and co-purification of NOLC1 and TCOF1 with FGF12-SPB on streptavidin agarose was verified by SDS-PAGE and western blotting. C Streptavidin-agarose pull-down from U2OS-FGF12-SPB cells to purify FGF12-SPB complexes under native conditions. Bound proteins were eluted with biotin and separated by 2D-BN-PAGE. Co-migration of FGF12-SPB and NOLC1 or TCOF1 was determined by western blotting.

**Additional file 4: Fig. S3.** Negative controls for in situ PLA performed in U2OS-FGF12-mGFP-myc cells. PLAs in U2OS-FGF12-mGFP-myc cells treated with a single antibody or in untreated cells. Nuclei were labeled with NucBlue Live and cells were analyzed with fluorescence microscopy. Scale bar represents 20 μm.

**Additional file 5: Fig. S4.** PLA in HEK 293 cells lacking ectopic FGF12. Fluorescence images of in situ PLA using rabbit anti-FGF12 and mouse anti-NOLC1 or anti-TCOF1 antibody in HEK 293 cells. HEK 293 cells treated with a single antibody or untreated showed no signal and served as negative controls. Nuclei were labeled with NucBlue Live and cells were analyzed with fluorescence microscopy. The dashed line indicates the cell area. The scale bar represents 20 μm.

**Additional file 6: Fig. S5.** Efficiency of NOLC1, TCOF1 and FGF12 knock-down in U2OS-FGF12-mGFP-myc cells. Western blotting analysis of cell lysates of U2OS-FGF12-mGFP-myc cells treated with siRNA against NOLC1, TCOF1 or FGF12.

**Additional file 7: Fig. S6.** Effect of NOLC1 and TCOF1 knock-down on the nucleolar localization of FGF12 and its interaction with NOLC1 and TCOF1. HEK 293 cells were transfected with NOLC1/TCOF1-targeting siRNA or scramble siRNA (control). Fluorescence images of in situ PLA using a mixture of rabbit anti-FGF12 and mouse anti-NOLC1 or anti-TCOF1 antibodies. Cell nuclei were labeled with NucBlue Live and cells were analyzed with fluorescence microscopy. The dashed line indicates the cell area. The scale bar represents 20 μm.

Acknowledgements

We thank Marta Minkiewicz for skillful support in cell culture, Dagmara Jakubowska for technical assistance and Karolina Jendryczko for providing the plasmid for FGF12-His.

Author contributions

Conceptualization: MZ, LO; Methodology: MS, LO, DK, MB, MZ; Validation: MS, LO; Formal analysis: MS; Investigation: MS, RK; Resources: MZ; Data curation: MS; Writing—original draft: MS, LO, MZ; Writing—review & editing: MS, LO, MZ; Visualization: MS, DK; Supervision: MZ; Project administration: MZ; Funding acquisition: MZ. All authors read and approved the final manuscript.

Funding

This work was funded by National Science Centre in Poland, OPUS grant 2019/31/B/NZ3/0166. Martyna Sochacka was also supported by PRzdLUM grant 2021/41/N/NZ3/01000.

Availability of data and materials

The datasets used in this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Author details

1Department of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Joliot-Curie 14a, 50-383 Wrocław, Poland. 2Department of Protein Biotechnology, Faculty of Biotechnology, University of Wrocław, Joliot-Curie 14a, 50-383 Wrocław, Poland.

Received: 25 August 2022 Accepted: 26 October 2022

Published online: 21 November 2022
voltage-gated Na+ channels and impairs neuronal excitability. J Neurosci. 2007;27:12033–44. https://doi.org/10.1523/JNEUROSCI.2282-07.2007.

14. Bosch MK, Nerbome JM, Townsend RR, Miyazaki H, Nakina N, Ornitz DM, et al. Proteomic analysis of native cerebellar FGF14 complexes.Channels. 2016;10:297–312. https://doi.org/10.1007/s41333-016-2131-6.

15. Lou JY, Laosza F, Gerber BR, Xiao M, Yamada KA, Hartmann H, et al. Fibroblast growth factor 14 is an intracellular modulator of voltage-gated sodium channels. J Physiol. 2005;569:179–93. https://doi.org/10.1113/JPHYSIOL.2005.097220.

16. Wildburger NC, Ali SR, Hsu WCJ, Shavkunov AS, Nenov MN, Lichti CF, et al. Quantitative proteomics reveals protein-protein interactions with fibroblast growth factor 12 as a component of the voltage-gated sodium channel 1.2 (Nav1.2) macromolecular complex in Mammalian brain. Mol Proteomics. 2015;14:1288–300. https://doi.org/10.1074/MCP.M14.040555.

17. Hsu WCJ, Scala F, Nenov MN, Wildburger NC, Effernik H, Singh AK, et al. CK2 activity is required for the interaction of FGF14 with voltage-gated sodium channels and neuronal excitability. FASEB J. 2016;30:2171–86. https://doi.org/10.1096/FJ.201500161.

18. Lee KW, Yim HS, Shin J, Lee C, Lee JH, Jeong YJ. FGF11 induced by hypoxia interacts with HIF-1α and enhances its stability. FEBBS Lett. 2017;591:348–57. https://doi.org/10.1002/1873-9688.201745.

19. Sun J, Ni CW, Liu RH, An N, Chen G, Huang Y, et al. FGF13 Is a Novel Regulator of NF-kB and Potentiates Pathological Cardiac Hypertrophy. Sci Transl Med. 2020;12:eabc0526. https://doi.org/10.1126/SCITRANSLMED.20201627.

20. Wadsworth PA, Folorunso O, Nguyen N, Singh AK, Dvorak NM, Orntsz DM, et al. JAK2 regulates Nav 1.6 channel function via FGF14 Y158 phosphorylation. Biochim Biophys Acta Mol Cell Res. 2020;1867:118786. https://doi.org/10.1016/j.bbamcr.2020.118786.

21. Shavkunov AS, Wildburger NC, Nenov MN, James TF, Buzhdygan TP, Panova-Elektronova NI, et al. The fibroblast growth factor 14-voltage-gated sodium channel complex Is a new target of glycogen synthase kinase 3 (GSK3). J Biol Chem. 2013;288:19370. https://doi.org/10.1074/JBC.M113.495249.

22. Re J, Wadsworth PA, Laurez F. Intracellular fibroblast growth factor 14: emerging risk factor for brain disorders. Front Cell Neurosci. 2017;11:103. https://doi.org/10.3389/FNEUR.2017.00103.

23. Hsu WCJ, Scala F, Nenov MN, Wildburger NC, Effernik H, Singh AK, et al. CK2 activity is required for the interaction of FGF14 with voltage-gated sodium channels and neuronal excitability. FASEB J. 2016;30:2171–86. https://doi.org/10.1096/FJ.201500161.

24. Lee KW, Yim HS, Shin J, Lee C, Lee JH, Jeong YJ. FGF11 induced by hypoxia interacts with HIF-1α and enhances its stability. FEBBS Lett. 2017;591:348–57. https://doi.org/10.1002/1873-9688.201745.

25. Sun J, Ni CW, Liu RH, An N, Chen G, Huang Y, et al. FGF13 Is a Novel Regulator of NF-kB and Potentiates Pathological Cardiac Hypertrophy. Sci Transl Med. 2020;12:eabc0526. https://doi.org/10.1126/SCITRANSLMED.20201627.

26. Wadsworth PA, Folorunso O, Nguyen N, Singh AK, Dvorak NM, Orntsz DM, et al. JAK2 regulates Nav 1.6 channel function via FGF14 Y158 phosphorylation. Biochim Biophys Acta Mol Cell Res. 2020;1867:118786. https://doi.org/10.1016/j.bbamcr.2020.118786.

27. Shavkunov AS, Wildburger NC, Nenov MN, James TF, Buzhdygan TP, Panova-Elektronova NI, et al. The fibroblast growth factor 14-voltage-gated sodium channel complex Is a new target of glycogen synthase kinase 3 (GSK3). J Biol Chem. 2013;288:19370. https://doi.org/10.1074/JBC.M113.495249.

28. Re J, Wadsworth PA, Laurez F. Intracellular fibroblast growth factor 14: emerging risk factor for brain disorders. Front Cell Neurosci. 2017;11:103. https://doi.org/10.3389/FNEUR.2017.00103.

29. Hsu WCJ, Scala F, Nenov MN, Wildburger NC, Effernik H, Singh AK, et al. CK2 activity is required for the interaction of FGF14 with voltage-gated sodium channels and neuronal excitability. FASEB J. 2016;30:2171–86. https://doi.org/10.1096/FJ.201500161.

30. Lee KW, Yim HS, Shin J, Lee C, Lee JH, Jeong YJ. FGF11 induced by hypoxia interacts with HIF-1α and enhances its stability. FEBBS Lett. 2017;591:348–57. https://doi.org/10.1002/1873-9688.201745.

31. Shavkunov AS, Wildburger NC, Nenov MN, James TF, Buzhdygan TP, Panova-Elektronova NI, et al. The fibroblast growth factor 14-voltage-gated sodium channel complex Is a new target of glycogen synthase kinase 3 (GSK3). J Biol Chem. 2013;288:19370. https://doi.org/10.1074/JBC.M113.495249.
47. Guella I, Huh L, McKenzie MB, Toyota EB, Bebin EM, Thompson ML, Cooper GM, Evans DM, Buerki SE, Adam S, Van Allen MI, Nelson TN, Connolly MB, Farner MJ, Demos M. De novo FGF12 mutation in 2 patients with neonatal-onset epilepsy. Neuril Genet. 2016;28(6):e120. https://doi.org/10.1212/NXG.0000000000000120.

48. Marin-Hernández E, Reyes-Salcedo CA, Cárdenas-Conjoe A, Peregrino-Bejarano L, Reyes-Cuayahuitl A, Raya-Mares D, et al. Tumorous congenital calcinosis cutis associated with early childhood epileptic encephalopathy with a pathogenic FGF12 gene variant. Biol Med Hosp Infant Mex. 2020;77:331–6. https://doi.org/10.24678/BMHIM.20000030.

49. Willemsen MH, Goel H, Verhoeven JS, Braakman HM, de Leeuw N, Freeth A, et al. Epilepsy phenotype in individuals with chromosomal duplication encompassing FGF12. Epilepsia Open. 2020;5:301–6. https://doi.org/10.1002/EP14.12396.

50. Tian Q, Li H, Shu L, Wang H, Peng Y, Fang H, et al. Effective treatments for FGF12-related early-onset epileptic encephalopathies patients. Brain Dev. 2021;43:851–6. https://doi.org/10.1016/J.BRINDEV.2021.04.010.

51. Wang X, Tang H, Wei EQ, Wang Z, Yang, J, Yang R, et al. Conditional knockout of Fgf13 in murine hearts increases arrhythmia susceptibility and reveals novel ion channel modulatory roles. J Mol Cell Cardiol. 2017;104:63–74. https://doi.org/10.1016/J.YJMCC.2017.01.009.

52. Musa H, Kline CF, Sturm AC, Murphy N, Adelman S, Wang C, et al. SCN5A variant that blocks fibroblast growth factor homologous factor regulation causes human arrhythmia. Proc Natl Acad Sci U S A. 2015;112:12528–33. https://doi.org/10.1073/PNAS.1516430112/SUPPLEMENTAL_FILE/PNAS.2015164305.PDF.

53. Hennessy JA, Marcou CA, Wang C, Wei EQ, Wang C, Tester DJ, et al. FGF12 is a candidate Brugada syndrome locus. Heart Rhythm Off J Heart Rhythm Soc. 2013;10:1866–94. https://doi.org/10.1016/J.HJRTHM.2013.09.064.

54. Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry SHC, Gilbert DJ, et al. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci U S A. 1996;93:9850–7. https://doi.org/10.1073/PNAS.93.18.9850.

55. Jin Y, Yu J, Yu YG. Identification of hNopp140 as a binding partner for doxycycline and calmodulin binds tightly to the N-terminal domain of A-type fibroblast growth factor homologous factors. J Biol Chem. 2018;293:140458. https://doi.org/10.1074/JBC.M118.005458.

56. Goldfarb M, Schoorlemmer J, Williams A, Diwakar S, Wang Q, Huang X, et al. Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated cardiac ion channels. Neuron. 2007;55:449–63. https://doi.org/10.1016/J.NEURON.2007.07.006.

57. Liu CJ, Dib-Hajj SD, Waxman SG. Fibroblast growth factor homologous factor 1B binds to the C terminus of the tetrodotoxin-resistant sodium channel Nav1.9 (NaV1.9). J Biol Chem. 2001;276:18925–33. https://doi.org/10.1074/JBC.M101660200.

58. Liu C, Dib-Hajj SD, Renganathan M, Cummins TR, Waxman SG. Modulation of the cardiac sodium channel Nav1.5 by fibroblast growth factor homologous factor 1B. J Biol Chem. 2003;278:1029–36. https://doi.org/10.1074/JBC.M207074200.

59. Jin Y, Yu J, Yu YG. Identification of hNopp140 as a binding partner for doxorubicin with a phage display cloning method. Chem Biol. 2002;9:157–62. https://doi.org/10.1016/S1074-5521(02)00096-0.

60. Thomas Meier U, Dobrowolska G, Krebs EG. Specific interaction between casein kinase 2 and the nucleolar protein Nopp140. J Biol Chem. 1997;272:3773–9. https://doi.org/10.1074/JBC.272.6.3773.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions